Biomarin Pharmaceutical Inc. (BMRN)
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market
BioMarin beats Q4 earnings estimates as Voxzogo drives year-over-year revenue growth. The company decides to voluntarily withdraw its hemophilia gene therapy.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.92 per share a year ago.
Countdown to BioMarin (BMRN) Q4 Earnings: Wall Street Forecasts for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for BioMarin (BMRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Right Play On BioMarin Pharmaceuticals
BioMarin Pharmaceuticals recently announced it is acquiring Amicus Therapeutics for $4.8B, adding two rare disease assets with blockbuster potential and strategic synergies. The acquisition provides insurance against competitive threats to Voxzogo, BMRN's key growth driver facing pressure from Ascendis and BridgeBio pipeline advances. The deal is initially slightly dilutive to 2026 non-GAAP EPS but is expected to be substantially accretive from 2027 as synergies and expansion opportunities materialize.
Should You Buy BioMarin Pharmaceutical Before Feb. 18?
BioMarin expects strong sales for its rare-disease drug, Voxzogo, in Q4. The company also has several important catalysts on the way in the first half of the year.
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
4 Value Stocks to Buy As Wall Street Weighs Trump Policies
As markets reel from policy uncertainty, UHS, PNC, GPN, and BMRN emerge as compelling value picks with strong cash flow.
BMRN or TARS: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Tarsus Pharmaceuticals, Inc. (TARS). But which of these two stocks is more attractive to value investors?
